Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

22,552 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    Biocon Settles With Bayer And Regeneron, Securing Canada Market Entry Date For Aflibercept Biosimilar

    On March 4, Biocon Biologics Ltd. announced it has signed a settlement agreement with Bayer Inc. and Regeneron Pharmaceuticals, Inc. regarding YESAFILI, Biocon's proposed biosimilar to EYLEA.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Celltrion Files Second Biosimilar Patent Lawsuit

    Celltrion Healthcare became the second company developing a biosimilar to file a declaratory judgment action before filing a licensure application.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
Jones Day
  • Article

    FDA Determines Regulatory Review Periods For Certain Drug Patents

    In recent issues of the Federal Register, FDA published its determinations of the regulatory review periods.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Publishes Notice Of Patent Infringement Complaint Filed Against A Biosimilar Applicant

    In the August 24, 2015, Federal Register, FDA announced that an applicant for a proposed biosimilar product had notified FDA that a patent infringement action has been filed in connection with the applicant's BLA.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    Federal Circuit Clarifies Supreme Court Ruling Regarding FDA Use Codes

    On July 30, 2012, the Federal Circuit issued a decision in Caraco Pharmaceuticals, Ltd. v. Novo Nordisk on remand from the Supreme Court.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Brinks Gilson & Lione
    Brinks Gilson & Lione
  • Article

    Final Text Of Trans-Pacific Partnership Released

    At long last, the final text of the Trans-Pacific Partnership, a free trade agreement among a dozen Pacific Rim nations, has now been made available to the public.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Patterson Belknap Webb & Tyler LLP
    Patterson Belknap Webb & Tyler LLP
  • Article

    Life Sciences Executive Exchange Series Session Two - Protecting And Defending Innovations

    In this series, designed for experienced pharma professionals and executives, Buchanan professionals will tackle critical issues to help you navigate the Pharma Product Lifecycle.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Buchanan Ingersoll & Rooney
    Buchanan Ingersoll & Rooney
  • Article

    Myriad's Impact On Nanotechnology? Nanotechnology's Impact On Myriad??

    On April 15, 2013, the Supreme Court will hear oral arguments in the Myriad Genetics v. Association for Molecular Pathology litigation.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Foley & Lardner LLP
    Foley & Lardner LLP
  • Article

    Podcast: Navigating Orange Book Listings

    The Drug Price Competition and Patent Term Restoration Act of 1984–also known as the Hatch-Waxman Act–amended patent law ...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Finnegan, Henderson, Farabow, Garrett & Dunner LLP
    Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • Article

    Preparing A Promising Drug Candidate For ANDA Litigation - Part 1

    Having a promising drug candidate in clinical trials can be an exciting time for a pharmaceutical company.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Finnegan, Henderson, Farabow, Garrett & Dunner LLP
    Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • Article

    Restrictions Governing International Trade In Genetic Resources Enter Into Force

    On 12 October 2014, the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits from their Utilization (‘the Protocol’) entered into international force.
    United StatesFood, Drugs, Healthcare, Life Sciences
    WilmerHale
    WilmerHale
  • Article

    Sandoz Launches Natalizumab Biosimilar

    On November 17, 2025, Sandoz announced the launch of TYRUKO® (natalizumab-sztn) in the United States as the first and only biosimilar for the treatment of relapsing forms of multiple sclerosis.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    To Dance Or Not To Dance: Biosimilar Strategies Post Amgen V Sandoz

    The Biologics Price Competition and Innovation Act (BPCIA) is a landmark piece of legislation signed into law by the Obama administration in 2009.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Fox Rothschild LLP
    Fox Rothschild LLP
  • Article

    Updates With Materials Genome Initiative, $25M Grants Announced; Complex IP Issues?

    The Office of Science and Technology Policy (OSTP) recently announced updates with the Materials Genonme Initiative (MGI). $25M in grants are noted, and the awardees include universities, national laboratories, and private sector companies (e.g., GM). Collaboration continues to be a strong theme.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Foley & Lardner LLP
    Foley & Lardner LLP
  • Article

    Venable's BiologicsHQ Monthly Injection – September 2023

    Venable's BiologicsHQ Monthly Injection – September 2023
    United StatesFood, Drugs, Healthcare, Life Sciences
    Venable LLP
    Venable LLP
  • Article

    Fastest 5 Minutes: Cybersecurity, Resellers, IP (Podcast)

    This week's episode covers developments regarding the Secure Software Development Attestation, GSA's newly release CUI guidance, GSA's RFI regarding resellers, and the Pentagon's "patent holiday" pilot...
    United StatesGovernment, Public Sector
    Crowell & Moring LLP
    Crowell & Moring LLP
  • Article

    USPTO To Remain Open ("For A Few Weeks") During Government Shutdown

    Further information regarding any adjustments to the USPTO's operating status will be posted on the USPTO website and delivered to the news media.
    United StatesGovernment, Public Sector
    Oblon
    Oblon
  • Article

    Partner Chris Gaspar Quoted in Law360 Article: "When AI Invents, Thorny Questions Follow For Patent Law"

    Milbank Partner Chris Gaspar recently commented in an article, "When AI Invents, Thorny Questions Follow For Patent Law," published by Law360.
    United StatesInsurance
    Milbank
    Milbank
  • Article

    #TBT Patents: Overly Revealing Fashionista Fail

    No, the person in front of you has not split her pants, but what she's wearing might have infringed this patent (had it not expired).
    United StatesIntellectual Property
    Troutman Pepper Locke LLP
    Troutman Pepper Locke LLP
  • Article

    10 Things Startups Can Do To Protect Intellectual Property (Videos)

    Our team of Fenwick attorneys prepared this short video about the most important steps to protect your startup ideas and brand, and avoid being targeted in a competitor's lawsuit.
    United StatesIntellectual Property
    Fenwick
    Fenwick
  • Showing 741–760 of 22552 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics